Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and Famitinib Strategy in TNBC
NCT05670925Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Mar 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, famitinib in triple-negative breast cancer (TNBC), sponsored by Fudan University. Status: unknown.
02
Drugs
camrelizumabfamitinib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05670925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05670925.